Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03048058 · ClinicalTrials.gov registry record · Phase 4
Internet Surveys and Their Impact on Adherence for Rosacea
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT03048058 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT03048058, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.
Interventions
- DRUG brimonidine topical gel 0.33% & survey
- DRUG brimonidine topical gel 0.33% & SOC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-05-05 |
| Est. Completion | 2017-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03048058
The ClinicalTrials.gov registry entry for NCT03048058 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which brimonidine topical gel 0.33% & survey is the first listed.
NCT03048058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03048058 about?
NCT03048058 is a clinical study titled "Internet Surveys and Their Impact on Adherence for Rosacea". An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per pac...
What is the current status of trial NCT03048058?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2016-05-05. Estimated completion is 2017-06.
What interventions are being tested in trial NCT03048058?
The interventions under investigation include: brimonidine topical gel 0.33% & survey (DRUG), brimonidine topical gel 0.33% & SOC (DRUG).
Who is sponsoring clinical trial NCT03048058?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.